Medsintez Plant LLC

Medsintez Plant LLC is a modern full-cycle biotechnological enterprise for development and production of pharmaceutical products complying with the international GMP requirements and ISO standards. The Medsintez Plant has been present on the Russian market for 20 years and is an active participant of drug import substitution programs in the Russian Federation.

The company produces genetically engineered and analogue human insulins Rosinsulin, a veterinary insulin Vinsuvet, a recombinant human follicle-stimulating hormone for the treatment of infertility Primapur, a recombinant human albumin, an innovative antiviral drug Triazavirin, hypoglycemic drugs Liraglutide and Semaglutide, infusion solutions and solutions for automated apheresis, as well as substances produced through chemical and biotechnological synthesis.

Main products of the enterprise are genetically engineered and analogue human insulins Rosinsulin, produced in cartridges, vials and pre-filled injection pens. The enterprise implements fully integrated production of the whole product range of genetically engineered human insulin Rosinsulin and analogue human insulins Rosinsulin Aspart R and Rosinsulin Glargine made of our own APIs. The plant also produces the first Russian veterinary species-specific insulin Vinsuvet, separately for cats and for dogs. In 2023, the Plant launched the production of a full cycle of hypoglycemic drugs for treating type II diabetes mellitus: Liraglutide and Semaglutide.

Triazavirin is a direct-acting antiviral drug developed by Russian scientists based on the original molecule. It is effective for the treatment and prevention of viral diseases, has a wide range of direct antiviral activity against RNA viral infections such as influenza, acute respiratory viral infection, COVID-19. Triazavirin is recommended by the Ministry of Health of the Russian Federation for treatment of influenza and ARVI in adults, and is the only direct-acting drug approved for prevention of COVID-19. Today, the company is developing a complex of antiviral drugs.

Primapur is the first Russian drug of recombinant human follicle-stimulating hormone for human infertility treatment, used in the in vitro fertilization and included in the List of Vital and Essential Drugs. Primapur is available in the form of an easy-to-use disposable injection pen. Today, the company is developing other hormonal drugs, used in a complex of assisted reproductive technologies, such as recombinant human chorionic gonadotropin, Cetrorelix and Ganirelix, which will ensure the drug safety in this area in Russia and enable it not to depend on import supplies.

In 2024 the full-cycle production of the world's first registered recombinant human albumin for widespread use in medicine was launched.

One of the major directions for development of the Medsintez Plant is contract manufacturing. Among partners of the enterprise are the largest international pharmaceutical companies such as Bayer, STADA, iVFarma, Promomed, etc.

High-tech Russian production at the Medsintez Plant ensures a high level of quality and safety of manufactured medicines. The company’s products are supplied to all regions of Russia. The production capacity of the plant is enough to cover 100% of the country’s needs for vital insulin medications and drugs for the treatment of infertility, as well as to provide major support to the country during epidemics and pandemics of viral infections.

15, Torgovaya St., Novouralsk, Sverdlovsk Region, Russia

Тel.: +7 (34370) 2-50-61

e-mail: medsintez@mail.ru

www.medsintez.com